Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2024-01-01 DOI:10.1016/j.curtheres.2024.100743

Yuyan Chen PM , Zhendong Fu MM , Xue Wen MM , Mingxia Zhang PM , Qiong Min PM , Peng Wang PM , Jin Zhang MB , Jun Ren PM , Wenbin Li PD , Rong Wang PD

{"title":"Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone","authors":"Yuyan Chen PM , Zhendong Fu MM , Xue Wen MM , Mingxia Zhang PM , Qiong Min PM , Peng Wang PM , Jin Zhang MB , Jun Ren PM , Wenbin Li PD , Rong Wang PD","doi":"10.1016/j.curtheres.2024.100743","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study aims to analyze a severe adverse reaction of pulmonary fibrosis induced by dronedarone hydrochloride tablets, and to provide a reference for clinical rational medication through drug precautions.</p></div><div><h3>Methods</h3><p>A case of pulmonary fibrosis induced by dronedarone hydrochloride tablets, along with related literature was retrospectively analyzed.</p></div><div><h3>Results</h3><p>Patients over 65 years old with a history of exposure to amiodarone may increase the incidence of pulmonary toxicity induced by dronedarone, and dronedarone should not be selected as a substitute treatment drug for patients with amiodarone-induced pulmonary toxicity.</p></div><div><h3>Conclusions</h3><p>It is recommended that clinicians monitor the diffusion capacity of carbon monoxide and lung ventilation function of patients before and after using dronedarone for treatment. For patients with a history of amiodarone exposure, intermittent monitoring of chest X-rays and lung function is necessary. If lung function decreases, dronedarone should be immediately discontinued.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100743"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000134/pdfft?md5=1f56ba5083d8a5b5645c5cf457bf46a5&pid=1-s2.0-S0011393X24000134-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X24000134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aims to analyze a severe adverse reaction of pulmonary fibrosis induced by dronedarone hydrochloride tablets, and to provide a reference for clinical rational medication through drug precautions.

Methods

A case of pulmonary fibrosis induced by dronedarone hydrochloride tablets, along with related literature was retrospectively analyzed.

Results

Patients over 65 years old with a history of exposure to amiodarone may increase the incidence of pulmonary toxicity induced by dronedarone, and dronedarone should not be selected as a substitute treatment drug for patients with amiodarone-induced pulmonary toxicity.

Conclusions

It is recommended that clinicians monitor the diffusion capacity of carbon monoxide and lung ventilation function of patients before and after using dronedarone for treatment. For patients with a history of amiodarone exposure, intermittent monitoring of chest X-rays and lung function is necessary. If lung function decreases, dronedarone should be immediately discontinued.

查看原文本刊更多论文

分析决奈达隆导致肺纤维化的严重不良反应

摘要】目的分析盐酸决奈达隆片剂诱发肺纤维化的严重不良反应，通过用药注意事项为临床合理用药提供参考。方法回顾性分析1例盐酸决奈达隆片剂诱发肺纤维化的病例及相关文献。结果65岁以上有胺碘酮接触史的患者可能会增加决奈达隆诱发肺毒性的发生率，不应选择决奈达隆作为胺碘酮诱发肺毒性患者的替代治疗药物。对于有胺碘酮接触史的患者，有必要间歇性监测胸部 X 光片和肺功能。如果肺功能下降，应立即停用决奈达隆。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.